[
    [
        {
            "time": "",
            "original_text": "康泰生物：中证鹏元终止公司可转换公司债券信用评级",
            "features": {
                "keywords": [
                    "康泰生物",
                    "中证鹏元",
                    "可转换公司债券",
                    "信用评级",
                    "终止"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：中证鹏元终止公司可转换公司债券信用评级",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物抛30亿定增分红仅7500万 研发费率4连降销售费用增近24倍 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "定增",
                    "分红",
                    "研发费率",
                    "销售费用",
                    "盈利能力",
                    "下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物抛30亿定增分红仅7500万 研发费率4连降销售费用增近24倍 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]